SCHEMBL4042334

SCHEMBL4042334

Cc1ccc(-n2nc(Nc3ccc4c(c3)OCO4)nc2N)nc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 3/20 0.47
MAPT P10636 4/20 0.46
GAA P10253 2/20 0.46
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
HTT P42858 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
LMNA P02545 2/20 0.45
KIT P10721 4/20 0.44
FLT3 P36888 4/20 0.44
AURKA O14965 1/20 0.44
JAK2 O60674 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
OGA O60502 1/20 0.43
BRD4 O60885 2/20 0.43
TP53 P04637 1/20 0.42
CLK1 P49759 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4042371 0.85 ULK1 (0.54) ULK1ALDH1A1SMN1; SMN2LMNAKIT
SCHEMBL4046024 0.85 FLT3 (0.56) ULK1LMNAKITFLT3AURKA
SCHEMBL4040721 0.83 AXL (0.51) KITFLT3AURKAJAK2IRAK4
SCHEMBL12845571 0.83 LMNA (0.45) ULK1MAPTGAAALDH1A1KDM4E
SCHEMBL4044007 0.83 FLT3 (0.62) GAASMN1; SMN2LMNAKITFLT3
SCHEMBL4042908 0.82 MAPT (0.47) ULK1MAPTGAAALDH1A1KDM4E
SCHEMBL2089408 0.82 IDO1 (0.50) ULK1MAPTGAAALDH1A1KDM4E
SCHEMBL6224723 0.79 ULK1 (0.44) ULK1MAPTGAAALDH1A1TDP1
SCHEMBL4040681 0.77 FLT3 (0.70) MAPTSMN1; SMN2LMNAKITFLT3
SCHEMBL4043587 0.76 FLT3 (0.64) KITFLT3AURKAJAK2IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
EP-2010493-A2 PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS Merck & Co., Inc. (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
WO-2007120729-A2 PYRIDYL AMIDE T-TYPE CALCIUM CHANNEL ANTAGONISTS MERCK & CO., INC. (US) 2007-10-25 WO disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 ULK1 257/4885MAPT 937/4885GAA 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.